Merck Stock Surges on Breakthrough Drug Trial Results and Pipeline Progress

Merck & Company Inc. stocks have surged by 7.4% after a series of positive developments, including breakthrough drug trial results and pipeline progress.

The upgrades from Daiwa to Outperform with a price target of $143 and JPMorgan's raised target to $150 have contributed significantly to the stock's rise.

Regulators have accepted Merck's applications to extend RSV protection for high-risk children under two, with a key FDA decision due on 2027/03/22. Additionally, Health Canada has approved KEYTRUDA with enfortumab vedotin for muscle-invasive bladder cancer.